Macrocyclic Peptide Complex for c-Met Agonist Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current peptide drugs targeting c-Met have limitations in stability and specificity, which hampers their effectiveness as both anticancer agents and regenerative therapy tools due to rapid degradation and low protease resistance.
Innovation Solution
A macrocyclic peptide complex is developed that binds to c-Met, promoting autophosphorylation and activating the c-Met signaling pathway, enhancing cell growth and migration, thereby improving stability and specificity through multimerization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide drugs are used to target c-Met, then specificity and physiological activity are improved, but protease resistance and stability are worsened
Solution Approach 1:
The patent applies macrocyclization to transform linear peptides into cyclic structures, creating a composite molecular architecture that combines the specificity of peptide-drug interactions with the enhanced stability of cyclic structures. This structural transformation provides resistance against proteolytic degradation while maintaining target binding capability
Solution Approach 2:
The patent modifies the structural parameters of peptides by introducing cyclic constraints through macrocyclization. This parameter change from linear to cyclic configuration fundamentally alters the peptide's resistance to protease degradation while preserving its ability to specifically bind to c-Met target molecules
2Reliability
If peptide drugs are used to target c-Met, then physiological activity is improved, but duration of action is worsened due to rapid degradation
Solution Approach 1:
The patent creates a composite molecular structure through macrocyclization that combines the functional advantages of peptide drugs with the stability advantages of cyclic structures, thereby extending the duration of action while maintaining physiological activity
Solution Approach 2:
By changing the structural parameter from linear to cyclic configuration, the patent extends the metabolic half-life of the peptide drug, thereby increasing its duration of action in the body while preserving its physiological effectiveness
3Stability of the object's composition
If macrocyclic peptide complex is used, then stability and specificity are improved, but device complexity is worsened
Solution Approach 1:
The patent divides the complex macrocyclic structure into modular repeating units that can be systematically assembled. Each unit contributes to the overall stability and specificity, allowing the complex structure to be constructed from standardized building blocks rather than as a monolithic complex
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide complex effectively promotes cell growth and migration, making it suitable for regenerative therapy and organ protection during transplantation, while maintaining stability and specificity.
Implementation Method 1
promotes autophosphorylation of c-Met proteins and activates a c-Met signaling pathway
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Object of the present invention is to provide a peptide functioning as a c-Met agonist. The present invention provides a peptide complex comprising two or more peptides that bind to a c-Met protein and a linker that links the two or more peptides to one another. Such a peptide complex promotes autophosphorylation of the c-Met protein and induces cell growth.